Top

Published in:

01-03-2016 | Original Article

SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma

Authors: Yang Yu, Yan Chen, Jianxia Ma, Xiaofeng Yu, Guanzhen Yu, Zhaoshen Li

Published in: Tumor Biology | Issue 3/2016

Abstract

Secreted protein acidic and rich in cysteines-like protein 1 (SPARCL1) has been implicated in tumor initiation, formation, and progression of various cancers, yet its role in hilar cholangiocarcinoma remains largely uncharacterized. In the present study, tissue microarrays containing resected hilar cholangiocarcinoma specimens from 92 patients were used to evaluate the expression of SPARCL1 protein by immunohistochemistry (IHC). In vitro assays were used to determine the effect of SPARCL1 overexpression on cell growth and migration. Loss of SPARCL1 expression was observed in 46 (50.0 %) of the 92 primary tumors. SPARCL1 expression is inversely associated with poorly or undifferentiation specimens (P = 0.030) in addition to lymph node metastasis (P = 0.047). Survival analysis demonstrated that SPARCL1 is an independent factor in predicting the outcome of patients with hilar cholangiocarcinoma. SPARCL1 overexpression suppressed tumor cell migration in vitro by inhibiting MMP-9, MMP-2, Vimentin, and Fibronectin expression, whereas did not inhibit cell proliferation in vitro. Our results suggest that loss of SPARCL1 is involved in the tumorigenesis of hilar cholangiocarcinoma and may serve as a novel molecular biomarker for patients’ outcome.

Available only for authorised users

Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatob Surg Nutrit. 2014;3(1):18–34.

Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol. 2009;15(34):4240–62.CrossRefPubMedPubMedCentral

Yi B, Zhang BH, Zhang YJ, Jiang XQ, Zhang BH, Yu WL, et al. Surgical procedure and prognosis of hilar cholangiocarcinoma. Hepatob Pancreat Dis Int. 2004;3(3):453–7.

Yubin L, Chihua F, Zhixiang J, Jinrui O, Zixian L, Jianghua Z, et al. Surgical management and prognostic factors of hilar cholangiocarcinoma: experience with 115 cases in China. Ann Surg Oncol. 2008;15(8):2113–9.CrossRefPubMed

Thelen A, Scholz A, Benckert C, Weichert W, Dietz E, Wiedenmann B, et al. Tumor-associated lymphangiogenesis correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. Ann Surg Oncol. 2008;15(3):791–9.CrossRefPubMed

Zhimin G, Noor H, Jian-Bo Z, Lin W, Jha RK. Advances in diagnosis and treatment of hilar cholangiocarcinoma—a review. Med Sci Monit. 2013;19:648–56.CrossRefPubMedPubMedCentral

Nagino M. Perihilar cholangiocarcinoma: a surgeon’s viewpoint on current topics. J Gastroenterol. 2012;47(11):1165–76.CrossRefPubMed

Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem. 2004;92(4):679–90.CrossRefPubMed

Bradshaw AD. Diverse biological functions of the SPARC family of proteins. Int J Biochem Cell Biol. 2012;44(3):480–8.CrossRefPubMedPubMedCentral

10.

Bendik I, Schraml P, Ludwig CU. Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. Cancer Res. 1998;58(4):626–9.PubMed

11.

Nelson PS, Plymate SR, Wang K, True LD, Ware JL, Gan L, et al. Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. Cancer Res. 1998;58(2):232–6.PubMed

12.

Claeskens A, Ongenae N, Neefs JM, Cheyns P, Kaijen P, Cools M, et al. Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer. 2000;82(6):1123–30.CrossRefPubMedPubMedCentral

13.

Isler SG, Schenk S, Bendik I, Schraml P, Novotna H, Moch H, et al. Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers. Int J Oncol. 2001;18(3):521–6.PubMed

14.

Hambrock HO, Nitsche DP, Hansen U, Bruckner P, Paulsson M, Maurer P, et al. SC1/hevin. An extracellular calcium-modulated protein that binds collagen I. J Biol Chem. 2003;278(13):11351–8.CrossRefPubMed

15.

Brekken RA, Sullivan MM, Workman G, Bradshaw AD, Carbon J, Siadak A, et al. Expression and characterization of murine hevin (SC1), a member of the SPARC family of matricellular proteins. J Histochem Cytochem. 2004;52(6):735–48.CrossRefPubMed

16.

Lively S, Ringuette MJ, Brown IR. Localization of the extracellular matrix protein SC1 to synapses in the adult rat brain. Neurochem Res. 2007;32(1):65–71.CrossRefPubMed

17.

Zhang H, Widegren E, Wang DW, Sun XF. SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer. Tumour Biol. 2011;32(6):1225–31.CrossRefPubMed

18.

Schellings MW, Vanhoutte D, Swinnen M, Cleutjens JP, Debets J, van Leeuwen RE, et al. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med. 2009;206(1):113–23.CrossRefPubMedPubMedCentral

19.

Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, et al. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A. 2012;109(37):14977–82.CrossRefPubMedPubMedCentral

20.

Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann BD, Strand DW, et al. SPARCL1 suppresses metastasis in prostate cancer. Mol Oncol. 2013;7(6):1019–30.CrossRefPubMed

21.

Cao F, Wang K, Zhu R, Hu YW, Fang WZ, Ding HZ. Clinicopathological significance of reduced SPARCL1 expression in human breast cancer. Asian Pac J Cancer Prev. 2013;14(1):195–200.CrossRefPubMed

22.

Turtoi A, Musmeci D, Naccarato AG, Scatena C, Ortenzi V, Kiss R, et al. Sparc-like protein 1 is a new marker of human glioma progression. J Proteome Res. 2012;11(10):5011–21.CrossRefPubMed

23.

Apra C, Richard L, Coulpier F, Blugeon C, Gilardi-Hebenstreit P, Vallat JM, et al. Cthrc1 is a negative regulator of myelination in Schwann cells. Glia. 2012;60(3):393–403.CrossRefPubMedPubMedCentral

24.

Hu H, Zhang H, Ge W, Liu X, Loera S, Chu P, et al. Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers. Clin Cancer Res. 2012;18(19):5438–48.CrossRefPubMed

25.

Esposito I, Kayed H, Keleg S, Giese T, Sage EH, Schirmacher P, et al. Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia. 2007;9(1):8–17.CrossRefPubMedPubMedCentral

26.

Fang W, Cui H, Yu D, Chen Y, Wang J, Yu G. Increased expression of phospho-acetyl-CoA carboxylase protein is an independent prognostic factor for human gastric cancer without lymph node metastasis. Med Oncol. 2014;31(7):15.CrossRefPubMed

27.

Yu G, Fang W, Xia T, Chen Y, Gao Y, Jiao X, Huang S, Wang J, Li Z, Xie. Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget 2015.

28.

Yu G, Wang J, Chen Y, Wang X, Pan J, Li Q, et al. Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer. Clin Exp Metastasis. 2008;25(7):695–702.CrossRefPubMed

29.

Ji Y, Xie M, Lan H, Zhang Y, Long Y, Weng H, et al. PRR11 is a novel gene implicated in cell cycle progression and lung cancer. Int J Biochem Cell Biol. 2013;45(3):645–56.CrossRefPubMed

30.

Sun Q, Yao X, Ning Y, Zhang W, Zhou G, Dong Y. Overexpression of response gene to complement 32 (RGC32) promotes cell invasion and induces epithelial-mesenchymal transition in lung cancer cells via the NF-kappaB signaling pathway. Tumour Biol J Int Soc Oncol Dev Biol Med. 2013;34(5):2995–3002.CrossRef

31.

Zaydfudim VM, Clark CJ, Kendrick ML, Que FG, Reid-Lombardo KM, Donohue JH, et al. Correlation of staging systems to survival in patients with resected hilar cholangiocarcinoma. Am J Surg. 2013;206(2):159–65.CrossRefPubMed

32.

Zervos EE, Osborne D, Goldin SB, Villadolid DV, Thometz DP, Durkin A, et al. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg. 2005;190(5):810–5.CrossRefPubMed

33.

Wang F, Liu Y, Zhang H. Loss of MTSS1 expression is an independent prognostic factor for hilar cholangiocarcinoma. Pathol Oncol Res. 2013;19(4):815–20.CrossRefPubMed

34.

Wang D, Zhang H, Fang Z, Yu G. Annexin-1 downregulation is associated with clinical outcome in Chinese patients with hilar cholangiocarcinoma. Eur Surg Res. 2010;45(3-4):151–7.CrossRefPubMed

35.

Shi RY, Yang XR, Shen QJ, Yang LX, Xu Y, Qiu SJ, et al. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. Cancer. 2013;119(5):993–1003.CrossRefPubMed

36.

Chen Y, Cha Z, Fang W, Qian B, Yu W, Li W, Yu G, Gao Y. The prognostic potential and oncogenic effects of PRR11 expression in hilar cholangiocarcinoma. Oncotarget 2015

37.

Obchoei S, Weakley SM, Wongkham S, Wongkham C, Sawanyawisuth K, Yao Q, et al. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma. Mol Cancer. 2011;10:102.CrossRefPubMedPubMedCentral

38.

Utispan K, Thuwajit P, Abiko Y, Charngkaew K, Paupairoj A, Chau-in S, et al. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer. 2010;9:13.CrossRefPubMedPubMedCentral

39.

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18(3):651–8.CrossRefPubMed

40.

Fokas E, Engenhart-Cabillic R, Daniilidis K, Rose F, An HX. Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev. 2007;26(3-4):705–15.CrossRefPubMed

41.

Yu WL, Cong WM, Zhang Y, Chen Y, Wang F, Yu G. Overexpression of ATA1/SLC38A1 predicts future recurrence and death in Chinese patients with hilar cholangiocarcinoma. J Surg Res. 2011;171(2):663–8.CrossRefPubMed

42.

Groblewska M, Siewko M, Mroczko B, Szmitkowski M. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiologica Pol Acad Sci Pol Histochem Cytochem Soc. 2012;50(1):12–9.CrossRef

43.

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–64.CrossRefPubMed

44.

Yang N, Hui L, Wang Y, Yang H, Jiang X. Overexpression of SOX2 promotes migration, invasion, and epithelial-mesenchymal transition through the Wnt/beta-catenin pathway in laryngeal cancer Hep-2 cells. Tumour Biol J Int Soc Oncol DEV Biol Med. 2014;35(8):7965–73.CrossRef

Title: SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma
Authors: Yang Yu
Yan Chen
Jianxia Ma
Xiaofeng Yu
Guanzhen Yu
Zhaoshen Li
Publication date: 01-03-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4206-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivo

RETRACTED ARTICLE: Tissue expression levels of miR-29b and miR-422a in children, adolescents, and young adults’ age groups and their association with prediction of poor prognosis in human osteosarcoma

Down-expression of miR-152 lead to impaired anti-tumor effect of NK via upregulation of HLA-G

Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient

microRNA-188 is downregulated in oral squamous cell carcinoma and inhibits proliferation and invasion by targeting SIX1

Interleukin-3 receptor α chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer